Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
Top Ad

Find Out

How to Find One Stock with Crorepati Potential? >> READ MORE

  • Home
  • Views On News
  • May 23, 2022 - Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend

May 23, 2022

Divis Lab Net Profit Rises 78%. Company Declares 1,500% Dividend

Pharma major Divi's Laboratories today reported its March quarter results during market hours.

The street was expecting the company to post muted numbers as there was a substantial decline in its Molnupiravir revenue. The company's exports of Molnupiravir API had declined.

There were also pricing pressures on two of its API products.

Ahead of its results, shares of the pharma company opened on a flat note at Rs 4,301 on the BSE.

The stock saw some buying after the quarterly numbers were announced as it rose over 2%.

Here are four key takeaways from Divi's Lab Q4 results.

  • The company's consolidated net profit came in at Rs 8.9 bn compared to Rs 5 bn reported in the same period last year.

    This translates into a 78% growth, which is not bad by any measures.
  • On the revenue front, the company saw a growth of 40.8% for the quarter under review to Rs 25.2 bn. The same figure in the previous year stood at Rs 17.9 bn.
  • For full year, the pharma major reported a 29% growth in its total revenue to Rs 90.7 bn.
  • Profit for the same period came in at Rs 29.6 bn as against a net profit of Rs 19.8 bn for the last year, reflecting a growth of 49%.
  • Divi's Lab recommended a dividend of Rs 30 per share, i.e., 1,500% on its face value of Rs 2.

The company's peer Dr Reddy's Lab recently reported its quarterly results where it saw a 76% de-growth in profit.

Divi's Lab share price opened the day flat against its previous close. As soon as it declared results, shares saw a sudden spike and rose over 2%.

In the past one year, shares of Divi's Lab have a muted performance to show (up 7%) while on a YTD basis, Divi's Lab has fallen 6%.

About Divi's Lab

Divi's Lab is a leading manufacturer of APIs (Active pharmaceuticals ingredients), intermediates and registered starting materials in India.

The company has been established for more than thirty years in Hyderabad, India and is among the top pharmaceutical companies in the country.

It has over 14,000 highly trained professionals across departments and 350 scientists that work together to bring world-class products to customers.

For more details about the company, you can have a look at Divi's Laboratories' factsheet and Divi's Laboratories' quarterly results on our website.

You can also compare Divi's Laboratories with its peers.

Divi's Laboratories vs Abbott India

Divi's Laboratories vs Sun Pharmaceuticals

Divi's Laboratories vs Aurobindo Pharma

Divi's Laboratories vs Cipla

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Equitymaster requests your view! Post a comment on "Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend". Click here!


More Views on News

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

Nifty Pharma Index - Bulls are Losing the Ground (Views On News)

Mar 16, 2022

For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks (Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling (Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively? (Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022 Views On News (Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover? (Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Jun 24, 2022 (Close)


  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks